Presence of autoantibodies in “seronegative” rheumatoid arthritis associates with classical risk factors and high disease activity
Background Rheumatoid arthritis (RA) is classified as seropositive or seronegative, depending on the presence/absence of rheumatoid factor (RF), primarily IgM RF, and/or anti-citrullinated protein antibodies (ACPA), commonly detected using anti-cyclic citrullinated peptide (CCP) assays. Known risk f...
Saved in:
| Published in | Arthritis research & therapy Vol. 22; no. 1; pp. 170 - 11 |
|---|---|
| Main Authors | , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central
16.07.2020
BioMed Central Ltd BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1478-6362 1478-6354 1478-6362 |
| DOI | 10.1186/s13075-020-02191-2 |
Cover
| Abstract | Background
Rheumatoid arthritis (RA) is classified as seropositive or seronegative, depending on the presence/absence of rheumatoid factor (RF), primarily IgM RF, and/or anti-citrullinated protein antibodies (ACPA), commonly detected using anti-cyclic citrullinated peptide (CCP) assays. Known risk factors associate with the more severe seropositive form of RA; less is known about seronegative RA. Here, we examine risk factors and clinical phenotypes in relation to presence of autoantibodies in the RA subset that is traditionally defined as seronegative.
Methods
Anti-CCP2 IgG, 19 ACPA fine-specificities, IgM/IgG/IgA RF, anti-carbamylated-protein (CarP) antibodies, and 17 other autoantibodies, were analysed in 2755 RA patients and 370 controls. Antibody prevalence, levels, and co-occurrence were examined, and associations with risk factors and disease activity during 5 years were investigated for different antibody-defined RA subsets.
Results
Autoantibodies were detected in a substantial proportion of the traditionally defined seronegative RA subset, with ACPA fine-specificities found in 30%, IgA/IgG RF in 9.4%, and anti-CarP antibodies in 16%, with a 9.6% co-occurrence of at least two types of RA-associated autoantibodies. HLA-DRB1 shared epitope (SE) associated with the presence of ACPA in anti-CCP2-negative RA; in anti-CCP2-positive RA, the SE association was defined by six ACPA fine-specificities with high co-occurrence. Smoking associated with RF, but not with ACPA, in anti-CCP2-negative RA. Presence of ACPA and RF, but not anti-CarP antibodies, in conventionally defined “seronegative” RA, associated with worse clinical outcome.
Conclusions
“Seronegative” RA is not truly a seronegative disease subset. Additional screening for ACPA fine-specificities and IgA/IgG RF defines a group of patients that resembles seropositive patients with respect to risk factors and clinical picture and may contribute to earlier diagnosis for a subset of anti-CCP2−/IgM RF− patients with a high need for active treatment. |
|---|---|
| AbstractList | Rheumatoid arthritis (RA) is classified as seropositive or seronegative, depending on the presence/absence of rheumatoid factor (RF), primarily IgM RF, and/or anti-citrullinated protein antibodies (ACPA), commonly detected using anti-cyclic citrullinated peptide (CCP) assays. Known risk factors associate with the more severe seropositive form of RA; less is known about seronegative RA. Here, we examine risk factors and clinical phenotypes in relation to presence of autoantibodies in the RA subset that is traditionally defined as seronegative.
Anti-CCP2 IgG, 19 ACPA fine-specificities, IgM/IgG/IgA RF, anti-carbamylated-protein (CarP) antibodies, and 17 other autoantibodies, were analysed in 2755 RA patients and 370 controls. Antibody prevalence, levels, and co-occurrence were examined, and associations with risk factors and disease activity during 5 years were investigated for different antibody-defined RA subsets.
Autoantibodies were detected in a substantial proportion of the traditionally defined seronegative RA subset, with ACPA fine-specificities found in 30%, IgA/IgG RF in 9.4%, and anti-CarP antibodies in 16%, with a 9.6% co-occurrence of at least two types of RA-associated autoantibodies. HLA-DRB1 shared epitope (SE) associated with the presence of ACPA in anti-CCP2-negative RA; in anti-CCP2-positive RA, the SE association was defined by six ACPA fine-specificities with high co-occurrence. Smoking associated with RF, but not with ACPA, in anti-CCP2-negative RA. Presence of ACPA and RF, but not anti-CarP antibodies, in conventionally defined "seronegative" RA, associated with worse clinical outcome.
"Seronegative" RA is not truly a seronegative disease subset. Additional screening for ACPA fine-specificities and IgA/IgG RF defines a group of patients that resembles seropositive patients with respect to risk factors and clinical picture and may contribute to earlier diagnosis for a subset of anti-CCP2-/IgM RF- patients with a high need for active treatment. Background Rheumatoid arthritis (RA) is classified as seropositive or seronegative, depending on the presence/absence of rheumatoid factor (RF), primarily IgM RF, and/or anti-citrullinated protein antibodies (ACPA), commonly detected using anti-cyclic citrullinated peptide (CCP) assays. Known risk factors associate with the more severe seropositive form of RA; less is known about seronegative RA. Here, we examine risk factors and clinical phenotypes in relation to presence of autoantibodies in the RA subset that is traditionally defined as seronegative. Methods Anti-CCP2 IgG, 19 ACPA fine-specificities, IgM/IgG/IgA RF, anti-carbamylated-protein (CarP) antibodies, and 17 other autoantibodies, were analysed in 2755 RA patients and 370 controls. Antibody prevalence, levels, and co-occurrence were examined, and associations with risk factors and disease activity during 5 years were investigated for different antibody-defined RA subsets. Results Autoantibodies were detected in a substantial proportion of the traditionally defined seronegative RA subset, with ACPA fine-specificities found in 30%, IgA/IgG RF in 9.4%, and anti-CarP antibodies in 16%, with a 9.6% co-occurrence of at least two types of RA-associated autoantibodies. HLA-DRB1 shared epitope (SE) associated with the presence of ACPA in anti-CCP2-negative RA; in anti-CCP2-positive RA, the SE association was defined by six ACPA fine-specificities with high co-occurrence. Smoking associated with RF, but not with ACPA, in anti-CCP2-negative RA. Presence of ACPA and RF, but not anti-CarP antibodies, in conventionally defined “seronegative” RA, associated with worse clinical outcome. Conclusions “Seronegative” RA is not truly a seronegative disease subset. Additional screening for ACPA fine-specificities and IgA/IgG RF defines a group of patients that resembles seropositive patients with respect to risk factors and clinical picture and may contribute to earlier diagnosis for a subset of anti-CCP2−/IgM RF− patients with a high need for active treatment. Abstract Background Rheumatoid arthritis (RA) is classified as seropositive or seronegative, depending on the presence/absence of rheumatoid factor (RF), primarily IgM RF, and/or anti-citrullinated protein antibodies (ACPA), commonly detected using anti-cyclic citrullinated peptide (CCP) assays. Known risk factors associate with the more severe seropositive form of RA; less is known about seronegative RA. Here, we examine risk factors and clinical phenotypes in relation to presence of autoantibodies in the RA subset that is traditionally defined as seronegative. Methods Anti-CCP2 IgG, 19 ACPA fine-specificities, IgM/IgG/IgA RF, anti-carbamylated-protein (CarP) antibodies, and 17 other autoantibodies, were analysed in 2755 RA patients and 370 controls. Antibody prevalence, levels, and co-occurrence were examined, and associations with risk factors and disease activity during 5 years were investigated for different antibody-defined RA subsets. Results Autoantibodies were detected in a substantial proportion of the traditionally defined seronegative RA subset, with ACPA fine-specificities found in 30%, IgA/IgG RF in 9.4%, and anti-CarP antibodies in 16%, with a 9.6% co-occurrence of at least two types of RA-associated autoantibodies. HLA-DRB1 shared epitope (SE) associated with the presence of ACPA in anti-CCP2-negative RA; in anti-CCP2-positive RA, the SE association was defined by six ACPA fine-specificities with high co-occurrence. Smoking associated with RF, but not with ACPA, in anti-CCP2-negative RA. Presence of ACPA and RF, but not anti-CarP antibodies, in conventionally defined “seronegative” RA, associated with worse clinical outcome. Conclusions “Seronegative” RA is not truly a seronegative disease subset. Additional screening for ACPA fine-specificities and IgA/IgG RF defines a group of patients that resembles seropositive patients with respect to risk factors and clinical picture and may contribute to earlier diagnosis for a subset of anti-CCP2−/IgM RF− patients with a high need for active treatment. Rheumatoid arthritis (RA) is classified as seropositive or seronegative, depending on the presence/absence of rheumatoid factor (RF), primarily IgM RF, and/or anti-citrullinated protein antibodies (ACPA), commonly detected using anti-cyclic citrullinated peptide (CCP) assays. Known risk factors associate with the more severe seropositive form of RA; less is known about seronegative RA. Here, we examine risk factors and clinical phenotypes in relation to presence of autoantibodies in the RA subset that is traditionally defined as seronegative. Anti-CCP2 IgG, 19 ACPA fine-specificities, IgM/IgG/IgA RF, anti-carbamylated-protein (CarP) antibodies, and 17 other autoantibodies, were analysed in 2755 RA patients and 370 controls. Antibody prevalence, levels, and co-occurrence were examined, and associations with risk factors and disease activity during 5 years were investigated for different antibody-defined RA subsets. Autoantibodies were detected in a substantial proportion of the traditionally defined seronegative RA subset, with ACPA fine-specificities found in 30%, IgA/IgG RF in 9.4%, and anti-CarP antibodies in 16%, with a 9.6% co-occurrence of at least two types of RA-associated autoantibodies. HLA-DRB1 shared epitope (SE) associated with the presence of ACPA in anti-CCP2-negative RA; in anti-CCP2-positive RA, the SE association was defined by six ACPA fine-specificities with high co-occurrence. Smoking associated with RF, but not with ACPA, in anti-CCP2-negative RA. Presence of ACPA and RF, but not anti-CarP antibodies, in conventionally defined "seronegative" RA, associated with worse clinical outcome. "Seronegative" RA is not truly a seronegative disease subset. Additional screening for ACPA fine-specificities and IgA/IgG RF defines a group of patients that resembles seropositive patients with respect to risk factors and clinical picture and may contribute to earlier diagnosis for a subset of anti-CCP2-/IgM RF- patients with a high need for active treatment. Background Rheumatoid arthritis (RA) is classified as seropositive or seronegative, depending on the presence/absence of rheumatoid factor (RF), primarily IgM RF, and/or anti-citrullinated protein antibodies (ACPA), commonly detected using anti-cyclic citrullinated peptide (CCP) assays. Known risk factors associate with the more severe seropositive form of RA; less is known about seronegative RA. Here, we examine risk factors and clinical phenotypes in relation to presence of autoantibodies in the RA subset that is traditionally defined as seronegative. Methods Anti-CCP2 IgG, 19 ACPA fine-specificities, IgM/IgG/IgA RF, anti-carbamylated-protein (CarP) antibodies, and 17 other autoantibodies, were analysed in 2755 RA patients and 370 controls. Antibody prevalence, levels, and co-occurrence were examined, and associations with risk factors and disease activity during 5 years were investigated for different antibody-defined RA subsets. Results Autoantibodies were detected in a substantial proportion of the traditionally defined seronegative RA subset, with ACPA fine-specificities found in 30%, IgA/IgG RF in 9.4%, and anti-CarP antibodies in 16%, with a 9.6% co-occurrence of at least two types of RA-associated autoantibodies. HLA-DRB1 shared epitope (SE) associated with the presence of ACPA in anti-CCP2-negative RA; in anti-CCP2-positive RA, the SE association was defined by six ACPA fine-specificities with high co-occurrence. Smoking associated with RF, but not with ACPA, in anti-CCP2-negative RA. Presence of ACPA and RF, but not anti-CarP antibodies, in conventionally defined "seronegative" RA, associated with worse clinical outcome. Conclusions "Seronegative" RA is not truly a seronegative disease subset. Additional screening for ACPA fine-specificities and IgA/IgG RF defines a group of patients that resembles seropositive patients with respect to risk factors and clinical picture and may contribute to earlier diagnosis for a subset of anti-CCP2-/IgM RF- patients with a high need for active treatment. Keywords: Rheumatoid arthritis (RA), Autoantibodies, Anti-citrullinated protein antibodies (ACPA), Cyclic citrullinated peptide (CCP), Rheumatoid factor (RF), Anti-carbamylated protein antibodies (anti-CarP), Disease activity score for 28 joints (DAS28), HLA-DRB1 shared epitope (SE), Smoking Rheumatoid arthritis (RA) is classified as seropositive or seronegative, depending on the presence/absence of rheumatoid factor (RF), primarily IgM RF, and/or anti-citrullinated protein antibodies (ACPA), commonly detected using anti-cyclic citrullinated peptide (CCP) assays. Known risk factors associate with the more severe seropositive form of RA; less is known about seronegative RA. Here, we examine risk factors and clinical phenotypes in relation to presence of autoantibodies in the RA subset that is traditionally defined as seronegative.BACKGROUNDRheumatoid arthritis (RA) is classified as seropositive or seronegative, depending on the presence/absence of rheumatoid factor (RF), primarily IgM RF, and/or anti-citrullinated protein antibodies (ACPA), commonly detected using anti-cyclic citrullinated peptide (CCP) assays. Known risk factors associate with the more severe seropositive form of RA; less is known about seronegative RA. Here, we examine risk factors and clinical phenotypes in relation to presence of autoantibodies in the RA subset that is traditionally defined as seronegative.Anti-CCP2 IgG, 19 ACPA fine-specificities, IgM/IgG/IgA RF, anti-carbamylated-protein (CarP) antibodies, and 17 other autoantibodies, were analysed in 2755 RA patients and 370 controls. Antibody prevalence, levels, and co-occurrence were examined, and associations with risk factors and disease activity during 5 years were investigated for different antibody-defined RA subsets.METHODSAnti-CCP2 IgG, 19 ACPA fine-specificities, IgM/IgG/IgA RF, anti-carbamylated-protein (CarP) antibodies, and 17 other autoantibodies, were analysed in 2755 RA patients and 370 controls. Antibody prevalence, levels, and co-occurrence were examined, and associations with risk factors and disease activity during 5 years were investigated for different antibody-defined RA subsets.Autoantibodies were detected in a substantial proportion of the traditionally defined seronegative RA subset, with ACPA fine-specificities found in 30%, IgA/IgG RF in 9.4%, and anti-CarP antibodies in 16%, with a 9.6% co-occurrence of at least two types of RA-associated autoantibodies. HLA-DRB1 shared epitope (SE) associated with the presence of ACPA in anti-CCP2-negative RA; in anti-CCP2-positive RA, the SE association was defined by six ACPA fine-specificities with high co-occurrence. Smoking associated with RF, but not with ACPA, in anti-CCP2-negative RA. Presence of ACPA and RF, but not anti-CarP antibodies, in conventionally defined "seronegative" RA, associated with worse clinical outcome.RESULTSAutoantibodies were detected in a substantial proportion of the traditionally defined seronegative RA subset, with ACPA fine-specificities found in 30%, IgA/IgG RF in 9.4%, and anti-CarP antibodies in 16%, with a 9.6% co-occurrence of at least two types of RA-associated autoantibodies. HLA-DRB1 shared epitope (SE) associated with the presence of ACPA in anti-CCP2-negative RA; in anti-CCP2-positive RA, the SE association was defined by six ACPA fine-specificities with high co-occurrence. Smoking associated with RF, but not with ACPA, in anti-CCP2-negative RA. Presence of ACPA and RF, but not anti-CarP antibodies, in conventionally defined "seronegative" RA, associated with worse clinical outcome."Seronegative" RA is not truly a seronegative disease subset. Additional screening for ACPA fine-specificities and IgA/IgG RF defines a group of patients that resembles seropositive patients with respect to risk factors and clinical picture and may contribute to earlier diagnosis for a subset of anti-CCP2-/IgM RF- patients with a high need for active treatment.CONCLUSIONS"Seronegative" RA is not truly a seronegative disease subset. Additional screening for ACPA fine-specificities and IgA/IgG RF defines a group of patients that resembles seropositive patients with respect to risk factors and clinical picture and may contribute to earlier diagnosis for a subset of anti-CCP2-/IgM RF- patients with a high need for active treatment. Rheumatoid arthritis (RA) is classified as seropositive or seronegative, depending on the presence/absence of rheumatoid factor (RF), primarily IgM RF, and/or anti-citrullinated protein antibodies (ACPA), commonly detected using anti-cyclic citrullinated peptide (CCP) assays. Known risk factors associate with the more severe seropositive form of RA; less is known about seronegative RA. Here, we examine risk factors and clinical phenotypes in relation to presence of autoantibodies in the RA subset that is traditionally defined as seronegative.Methods: Anti-CCP2 IgG, 19 ACPA fine-specificities, IgM/IgG/IgA RF, anti-carbamylated-protein (CarP) antibodies, and 17 other autoantibodies, were analysed in 2755 RA patients and 370 controls. Antibody prevalence, levels, and co-occurrence were examined, and associations with risk factors and disease activity during 5 years were investigated for different antibody-defined RA subsets.Results:Autoantibodies were detected in a substantial proportion of the traditionally defined seronegative RA subset, with ACPA fine-specificities found in 30%, IgA/IgG RF in 9.4%, and anti-CarP antibodies in 16%, with a 9.6% co-occurrence of at least two types of RA-associated autoantibodies. HLA-DRB1 shared epitope (SE) associated with the presence of ACPA in anti-CCP2-negative RA; in anti-CCP2-positive RA, the SE association was defined by six ACPA fine-specificities with high co-occurrence. Smoking associated with RF, but not with ACPA, in anti-CCP2-negative RA. Presence of ACPA and RF, but not anti-CarP antibodies, in conventionally defined “seronegative” RA, associated with worse clinical outcome.Conclusions:“Seronegative” RA is not truly a seronegative disease subset. Additional screening for ACPA fine-specificities and IgA/IgG RF defines a group of patients that resembles seropositive patients with respect to risk factors and clinical picture and may contribute to earlier diagnosis for a subset of anti-CCP2−/IgM RF− patients with a high need for active treatment.Keywords: Rheumatoid arthritis (RA), Autoantibodies, Anti-citrullinated protein antibodies (ACPA), Cyclic citrullinated peptide (CCP), Rheumatoid factor (RF), Anti-carbamylated protein antibodies (anti-CarP), Disease activity score for 28 joints (DAS28), HLA-DRB1 shared epitope (SE), Smoking Background Rheumatoid arthritis (RA) is classified as seropositive or seronegative, depending on the presence/absence of rheumatoid factor (RF), primarily IgM RF, and/or anti-citrullinated protein antibodies (ACPA), commonly detected using anti-cyclic citrullinated peptide (CCP) assays. Known risk factors associate with the more severe seropositive form of RA; less is known about seronegative RA. Here, we examine risk factors and clinical phenotypes in relation to presence of autoantibodies in the RA subset that is traditionally defined as seronegative. Methods Anti-CCP2 IgG, 19 ACPA fine-specificities, IgM/IgG/IgA RF, anti-carbamylated-protein (CarP) antibodies, and 17 other autoantibodies, were analysed in 2755 RA patients and 370 controls. Antibody prevalence, levels, and co-occurrence were examined, and associations with risk factors and disease activity during 5 years were investigated for different antibody-defined RA subsets. Results Autoantibodies were detected in a substantial proportion of the traditionally defined seronegative RA subset, with ACPA fine-specificities found in 30%, IgA/IgG RF in 9.4%, and anti-CarP antibodies in 16%, with a 9.6% co-occurrence of at least two types of RA-associated autoantibodies. HLA-DRB1 shared epitope (SE) associated with the presence of ACPA in anti-CCP2-negative RA; in anti-CCP2-positive RA, the SE association was defined by six ACPA fine-specificities with high co-occurrence. Smoking associated with RF, but not with ACPA, in anti-CCP2-negative RA. Presence of ACPA and RF, but not anti-CarP antibodies, in conventionally defined “seronegative” RA, associated with worse clinical outcome. Conclusions “Seronegative” RA is not truly a seronegative disease subset. Additional screening for ACPA fine-specificities and IgA/IgG RF defines a group of patients that resembles seropositive patients with respect to risk factors and clinical picture and may contribute to earlier diagnosis for a subset of anti-CCP2−/IgM RF− patients with a high need for active treatment. |
| ArticleNumber | 170 |
| Audience | Academic |
| Author | Reed, Evan Skriner, Karl Mathsson-Alm, Linda Hedström, Anna Karin Rönnelid, Johan Saevarsdottir, Saedis Lundberg, Karin Serre, Guy Brynedal, Boel Jakobsson, Per-Johan Cornillet, Martin Alfredsson, Lars Holmdahl, Rikard Hansson, Monika |
| Author_xml | – sequence: 1 givenname: Evan surname: Reed fullname: Reed, Evan organization: Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital – sequence: 2 givenname: Anna Karin surname: Hedström fullname: Hedström, Anna Karin organization: Institute of Environmental Medicine, Karolinska Institutet, Department of Clinical Neuroscience, Karolinska Institutet – sequence: 3 givenname: Monika surname: Hansson fullname: Hansson, Monika organization: Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital – sequence: 4 givenname: Linda surname: Mathsson-Alm fullname: Mathsson-Alm, Linda organization: Thermo Fisher Scientific, Department of Immunology Genetics and Pathology, Uppsala University – sequence: 5 givenname: Boel surname: Brynedal fullname: Brynedal, Boel organization: Institute of Environmental Medicine, Karolinska Institutet – sequence: 6 givenname: Saedis surname: Saevarsdottir fullname: Saevarsdottir, Saedis organization: Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Faculty of Medicine, School of Health Sciences, University of Iceland – sequence: 7 givenname: Martin surname: Cornillet fullname: Cornillet, Martin organization: Unité Différenciation Epithéliale et Autoimmunité Rhumatoïde, Université de Toulouse-INSERM UMR 1056 – sequence: 8 givenname: Per-Johan surname: Jakobsson fullname: Jakobsson, Per-Johan organization: Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital – sequence: 9 givenname: Rikard surname: Holmdahl fullname: Holmdahl, Rikard organization: Section for Medical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institutet – sequence: 10 givenname: Karl surname: Skriner fullname: Skriner, Karl organization: Department of Rheumatology and Clinical Immunology, Charité University – sequence: 11 givenname: Guy surname: Serre fullname: Serre, Guy organization: Unité Différenciation Epithéliale et Autoimmunité Rhumatoïde, Université de Toulouse-INSERM UMR 1056 – sequence: 12 givenname: Lars surname: Alfredsson fullname: Alfredsson, Lars organization: Institute of Environmental Medicine, Karolinska Institutet, Department of Clinical Neuroscience, Karolinska Institutet, Centre for Occupational and Environmental Medicine, Region Stockholm – sequence: 13 givenname: Johan surname: Rönnelid fullname: Rönnelid, Johan organization: Department of Immunology Genetics and Pathology, Uppsala University – sequence: 14 givenname: Karin orcidid: 0000-0001-7625-964X surname: Lundberg fullname: Lundberg, Karin email: Karin.Lundberg@ki.se organization: Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32678001$$D View this record in MEDLINE/PubMed https://ut3-toulouseinp.hal.science/hal-03152228$$DView record in HAL https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-420437$$DView record from Swedish Publication Index http://kipublications.ki.se/Default.aspx?queryparsed=id:144266058$$DView record from Swedish Publication Index |
| BookMark | eNp9k8tu1DAUhiNURC_wAixQJDYgkeJLYjsbpFG5tFIlWABby-PYE7eZuNjOVN11xVPAy_VJOJmZ0s4IqiiKc_L9v-PfPvvZTu97k2XPMTrEWLC3EVPEqwIRBDeucUEeZXu45KJglJGde-PdbD_GM4QIqUn5JNulhHGBEN7Lfn4JJppem9zbXA3Jqz65qW-cibnr85vrX9EEmHamkluYm-vfeWjNMFfJuyZXIbXBJRdzFaPXTiVQXbrU5rqDitOqy4OL57lVOvkAWN_krZu1eeOiUdHkUHcLl66eZo-t6qJ5tn4eZN8-fvh6dFycfv50cjQ5LTTHLBVMVEg1iFNEWFNZS7ipcKVpaeup0NoIhKkyitbGNg2qhS2ZnsIrFcoKyzA9yE5Wvo1XZ_IiuLkKV9IrJ5cFH2YSFuV0Z2RtypKUzDLORamZqFnJSaOmXCmEGlyDV7HyipfmYphuuK1L5zAysmQ14wj4N__l37vvk-XswyBLgkrKAX-3woGdm0abPgXVbag2v_SulTO_kJyysqICDF6vDNot2fHkVI41RHFFCBGLMZdX68mC_zGYmOTcRW26TvXGD1ESiKKuIYQRfbmFnvkh9LBrS4pjQrm4o2YKsnS99fCPejSVE0axqCvCCVCH_6DgaszcaTh21kF9Q_Difih_l3V7oAEQK0AHH2MwVmqX4Oz6MSPXSYzk2Dty1TsSekcue0eO3mRLeuv-oIiuNxXgfmbCXRoPqP4AQMIuTA |
| CitedBy_id | crossref_primary_10_47360_1995_4484_2022_314_326 crossref_primary_10_1007_s11298_021_1926_1 crossref_primary_10_1016_j_clim_2024_110425 crossref_primary_10_1007_s00296_023_05445_9 crossref_primary_10_1111_imm_13412 crossref_primary_10_1080_14397595_2021_1913277 crossref_primary_10_1097_01_NME_0000936408_67405_c6 crossref_primary_10_1002_acr_25335 crossref_primary_10_1136_ard_2024_226024 crossref_primary_10_3389_fimmu_2021_692041 crossref_primary_10_1016_j_autrev_2022_103143 crossref_primary_10_3389_fimmu_2024_1447213 crossref_primary_10_3389_fmed_2022_824501 crossref_primary_10_47360_1995_4484_2023_276_291 crossref_primary_10_3390_biomedicines12030616 crossref_primary_10_3390_diagnostics12071661 crossref_primary_10_3389_fimmu_2023_1221125 crossref_primary_10_1038_s41598_024_55004_w crossref_primary_10_1007_s12016_021_08890_1 crossref_primary_10_3389_fmed_2022_689711 crossref_primary_10_1007_s15016_022_9432_6 crossref_primary_10_1016_j_ultrasmedbio_2023_06_017 crossref_primary_10_1007_s15202_021_4640_7 crossref_primary_10_1016_j_immuni_2022_11_009 crossref_primary_10_1093_rheumatology_keac657 crossref_primary_10_1111_sji_13151 crossref_primary_10_1134_S1607672924700960 crossref_primary_10_1016_j_berh_2021_101740 crossref_primary_10_1002_eji_202149279 crossref_primary_10_1136_rmdopen_2023_003851 crossref_primary_10_47836_mjmhs_19_1_14 crossref_primary_10_3389_fimmu_2022_804822 crossref_primary_10_1186_s13075_022_02945_0 crossref_primary_10_1007_s10067_022_06432_4 crossref_primary_10_3899_jrheum_2023_0907 crossref_primary_10_3390_cells10113017 crossref_primary_10_1038_s41598_021_96675_z crossref_primary_10_1002_art_42463 crossref_primary_10_1093_rheumatology_keac601 crossref_primary_10_1111_resp_14543 crossref_primary_10_3389_fimmu_2021_627986 crossref_primary_10_1016_j_jbspin_2025_105869 crossref_primary_10_47360_1995_4484_2023_751_757 crossref_primary_10_1002_art_42428 crossref_primary_10_1093_rheumatology_keab838 crossref_primary_10_1002_acr2_11767 crossref_primary_10_1038_s41598_023_32428_4 crossref_primary_10_1007_s10067_022_06315_8 crossref_primary_10_3389_fimmu_2021_666114 crossref_primary_10_1002_cti2_1288 crossref_primary_10_1021_acsomega_2c05749 crossref_primary_10_4155_bio_2023_0130 crossref_primary_10_1093_cei_uxad076 crossref_primary_10_1097_BOR_0000000000001006 crossref_primary_10_1093_rheumatology_keae382 |
| Cites_doi | 10.1136/annrheumdis-2015-208873 10.1093/rheumatology/keh365 10.1136/annrheumdis-2013-204591 10.1136/ard.2007.082669 10.3389/fimmu.2018.00876 10.1002/art.40237 10.1186/s13075-016-1177-9 10.1002/art.23596 10.1136/ard.62.9.835 10.1136/annrheumdis-2013-203915 10.1093/rheumatology/kep045 10.1136/ard.2010.138461 10.1002/art.20553 10.1136/annrheumdis-2013-205109 10.1016/j.ajhg.2019.08.002 10.1136/annrheumdis-2017-211782 10.1136/annrheumdis-2012-201484 10.1186/s13075-015-0690-6 10.1002/art.21575 10.4049/jimmunol.166.6.4177 10.1002/art.40678 10.1136/ard.2009.126821 10.1007/s10067-007-0812-x 10.1136/annrheumdis-2014-206785 10.1002/art.40698 10.1136/ard.61.12.1090 10.1136/annrheumdis-2012-203130 10.1002/art.23936 10.1136/annrheumdis-2015-208495 10.1002/art.40587 10.1186/ar4039 10.1016/j.ajhg.2010.12.007 10.1002/art.27758 10.1002/art.39170 10.1136/ard.2004.033571 10.1371/journal.pone.0035296 10.1073/pnas.1114465108 10.1186/ar1149 10.1002/art.39619 10.1172/JCI45790 10.1002/art.40578 10.1002/art.1780310302 10.1002/art.40699 10.1136/annrheumdis-2011-201225 10.1186/s13075-015-0611-8 10.1038/gene.2012.46 10.1136/ard.2003.019877 10.1002/eji.200526000 10.1086/498651 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2020 COPYRIGHT 2020 BioMed Central Ltd. 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Distributed under a Creative Commons Attribution 4.0 International License |
| Copyright_xml | – notice: The Author(s) 2020 – notice: COPYRIGHT 2020 BioMed Central Ltd. – notice: 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Distributed under a Creative Commons Attribution 4.0 International License |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 1XC VOOES 5PM ACNBI ADTPV AOWAS D8T DF2 ZZAVC DOA |
| DOI | 10.1186/s13075-020-02191-2 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) PHMC-Proquest健康医学期刊库 ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials - QC ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic Hyper Article en Ligne (HAL) Hyper Article en Ligne (HAL) (Open Access) PubMed Central (Full Participant titles) SWEPUB Uppsala universitet full text SwePub SwePub Articles SWEPUB Freely available online SWEPUB Uppsala universitet SwePub Articles full text DOAJ (Directory of Open Access Journals) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: Directory of Open Access Journals (DOAJ) url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1478-6362 |
| EndPage | 11 |
| ExternalDocumentID | oai_doaj_org_article_9e44246f67784c6896472dab7aa00d19 oai_swepub_ki_se_469670 oai_DiVA_org_uu_420437 PMC7364538 oai_HAL_hal_03152228v1 A631895272 32678001 10_1186_s13075_020_02191_2 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Sweden |
| GeographicLocations_xml | – name: Sweden |
| GrantInformation_xml | – fundername: Stiftelsen Konung Gustaf V:s 80-årsfond grantid: FAI-2016-0273 funderid: http://dx.doi.org/10.13039/501100007857 – fundername: Vetenskapsrådet grantid: 2017-01696 funderid: http://dx.doi.org/10.13039/501100004359 – fundername: Innovative Medicines Initiative (RTCure) grantid: 777357 – fundername: FP7-Health (Trigger) grantid: 2013-306029 – fundername: Innovative Medicines Initiative (BeTheCure) grantid: 115142 – fundername: ; grantid: 2017-01696 – fundername: ; grantid: FAI-2016-0273 – fundername: ; grantid: 777357 – fundername: ; grantid: 2013-306029 – fundername: ; grantid: 115142 |
| GroupedDBID | --- .GJ 0R~ 23N 2WC 4.4 5GY 5VS 6J9 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML ABUWG ACGFS ACJQM ADBBV ADUKV AEGXH AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIAM AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK E3Z EBD EBLON EMOBN F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE HZ~ INH INR ITC KQ8 M1P O5R O5S O9- PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ ROL RPM RSV SMD SOJ SV3 TR2 U2A UKHRP WOQ AAYXX ALIPV CITATION CGR CUY CVF ECM EIF NPM PMFND 3V. 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQUKI PRINS 7X8 1XC 53G AHSBF C1A EJD H13 VOOES ZGI 5PM ACNBI ADTPV AOWAS D8T DF2 ZZAVC |
| ID | FETCH-LOGICAL-c716t-6850ad073026d5ff27e515c34f9b8cce8013aea39efdd098f46cba3938af8f613 |
| IEDL.DBID | C6C |
| ISSN | 1478-6362 1478-6354 |
| IngestDate | Wed Aug 27 01:23:38 EDT 2025 Wed Sep 24 03:53:58 EDT 2025 Tue Sep 09 23:19:55 EDT 2025 Thu Aug 21 18:30:57 EDT 2025 Fri Sep 12 12:45:37 EDT 2025 Thu Sep 04 20:16:52 EDT 2025 Fri Jul 25 06:08:15 EDT 2025 Tue Jun 17 20:56:09 EDT 2025 Tue Jun 10 20:12:44 EDT 2025 Thu Apr 03 07:03:37 EDT 2025 Thu Apr 24 23:12:25 EDT 2025 Tue Jul 01 04:00:55 EDT 2025 Sat Sep 06 07:28:17 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Rheumatoid arthritis (RA) Anti-carbamylated protein antibodies (anti-CarP) Autoantibodies Cyclic citrullinated peptide (CCP) Disease activity score for 28 joints (DAS28) Rheumatoid factor (RF) Anti-citrullinated protein antibodies (ACPA) HLA-DRB1 shared epitope (SE) Smoking |
| Language | English |
| License | Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c716t-6850ad073026d5ff27e515c34f9b8cce8013aea39efdd098f46cba3938af8f613 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0001-7625-964X 0000-0001-7981-0927 |
| OpenAccessLink | https://doi.org/10.1186/s13075-020-02191-2 |
| PMID | 32678001 |
| PQID | 2424712378 |
| PQPubID | 42876 |
| PageCount | 11 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_9e44246f67784c6896472dab7aa00d19 swepub_primary_oai_swepub_ki_se_469670 swepub_primary_oai_DiVA_org_uu_420437 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7364538 hal_primary_oai_HAL_hal_03152228v1 proquest_miscellaneous_2424996891 proquest_journals_2424712378 gale_infotracmisc_A631895272 gale_infotracacademiconefile_A631895272 pubmed_primary_32678001 crossref_citationtrail_10_1186_s13075_020_02191_2 crossref_primary_10_1186_s13075_020_02191_2 springer_journals_10_1186_s13075_020_02191_2 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2020-07-16 |
| PublicationDateYYYYMMDD | 2020-07-16 |
| PublicationDate_xml | – month: 07 year: 2020 text: 2020-07-16 day: 16 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Arthritis research & therapy |
| PublicationTitleAbbrev | Arthritis Res Ther |
| PublicationTitleAlternate | Arthritis Res Ther |
| PublicationYear | 2020 |
| Publisher | BioMed Central BioMed Central Ltd BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
| References | S Saevarsdottir (2191_CR27) 2011; 63 K Lundberg (2191_CR13) 2008; 58 FC Arnett (2191_CR23) 1988; 31 C Ge (2191_CR35) 2019; 71 S Viatte (2191_CR4) 2016; 68 VFAM Derksen (2191_CR32) 2018; 70 2191_CR36 A Schwenzer (2191_CR15) 2016; 75 J Shi (2191_CR21) 2011; 108 J Rönnelid (2191_CR19) 2018; 77 F Kurreeman (2191_CR2) 2011; 88 CA Wagner (2191_CR17) 2015; 74 I Peene (2191_CR22) 2002; 61 J Sokolove (2191_CR14) 2012; 7 A Svärd (2191_CR48) 2015; 67 D Sieghart (2191_CR30) 2018; 9 L Klareskog (2191_CR29) 2006; 54 G Westhoff (2191_CR9) 2009; 48 RM Plenge (2191_CR26) 2005; 77 L Menard (2191_CR47) 2011; 121 S Viatte (2191_CR44) 2012; 71 J Zheng (2191_CR46) 2012; 13 L Bossini-Castillo (2191_CR45) 2015; 74 LB Nordberg (2191_CR6) 2017; 76 L Padyukov (2191_CR3) 2011; 70 M Hansson (2191_CR18) 2012; 14 T Korpilahde (2191_CR42) 2004; 43 M-E Truchetet (2191_CR31) 2017; 69 D Murphy (2191_CR38) 2017; 12 J Rönnelid (2191_CR5) 2005; 64 TJ van Wesemael (2191_CR39) 2016; 18 J Steen (2191_CR33) 2019; 71 ML Harris (2191_CR49) 2008; 58 I Vallbracht (2191_CR20) 2004; 63 M Juarez (2191_CR50) 2016; 75 KMJ Janssen (2191_CR41) 2015; 17 X Jiang (2191_CR28) 2014; 73 ER Vossenaar (2191_CR11) 2004; 6 P Stolt (2191_CR24) 2003; 62 JAB van Nies (2191_CR8) 2014; 73 SE Elliott (2191_CR34) 2018; 70 DR Lu (2191_CR37) 2018; 70 TR Mikuls (2191_CR40) 2008; 67 P Verschueren (2191_CR7) 2015; 17 D Aletaha (2191_CR1) 2010; 69 H Burkhardt (2191_CR12) 2005; 35 C Masson-Bessière (2191_CR10) 2001; 166 K Lundberg (2191_CR16) 2013; 72 E Schneeberger (2191_CR43) 2008; 27 L Padyukov (2191_CR25) 2004; 50 |
| References_xml | – volume: 76 start-page: 341 issue: 2 year: 2017 ident: 2191_CR6 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2015-208873 – volume: 43 start-page: 1424 issue: 11 year: 2004 ident: 2191_CR42 publication-title: Rheumatology (Oxford) doi: 10.1093/rheumatology/keh365 – volume: 74 start-page: e15 issue: 3 year: 2015 ident: 2191_CR45 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2013-204591 – volume: 67 start-page: 1529 issue: 11 year: 2008 ident: 2191_CR40 publication-title: Ann Rheum Dis doi: 10.1136/ard.2007.082669 – volume: 9 start-page: 876 year: 2018 ident: 2191_CR30 publication-title: Front Immunol doi: 10.3389/fimmu.2018.00876 – volume: 69 start-page: 2292 issue: 12 year: 2017 ident: 2191_CR31 publication-title: Arthritis Rheumatol doi: 10.1002/art.40237 – volume: 18 start-page: 285 issue: 1 year: 2016 ident: 2191_CR39 publication-title: Arthritis Res Ther doi: 10.1186/s13075-016-1177-9 – volume: 58 start-page: 1958 issue: 7 year: 2008 ident: 2191_CR49 publication-title: Arthritis Rheum doi: 10.1002/art.23596 – volume: 62 start-page: 835 issue: 9 year: 2003 ident: 2191_CR24 publication-title: Ann Rheum Dis doi: 10.1136/ard.62.9.835 – volume: 12 issue: 7 year: 2017 ident: 2191_CR38 publication-title: PLoS One – volume: 74 start-page: 579 issue: 3 year: 2015 ident: 2191_CR17 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2013-203915 – volume: 48 start-page: 650 issue: 6 year: 2009 ident: 2191_CR9 publication-title: Rheumatology (Oxford) doi: 10.1093/rheumatology/kep045 – volume: 69 start-page: 1580 issue: 9 year: 2010 ident: 2191_CR1 publication-title: Ann Rheum Dis doi: 10.1136/ard.2010.138461 – volume: 50 start-page: 3085 issue: 10 year: 2004 ident: 2191_CR25 publication-title: Arthritis Rheum doi: 10.1002/art.20553 – volume: 73 start-page: 1761 issue: 10 year: 2014 ident: 2191_CR28 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2013-205109 – ident: 2191_CR36 doi: 10.1016/j.ajhg.2019.08.002 – volume: 77 start-page: 203 issue: 2 year: 2018 ident: 2191_CR19 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2017-211782 – volume: 72 start-page: 652 issue: 5 year: 2013 ident: 2191_CR16 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2012-201484 – volume: 17 start-page: 174 issue: 1 year: 2015 ident: 2191_CR41 publication-title: Arthritis Res Ther. doi: 10.1186/s13075-015-0690-6 – volume: 54 start-page: 38 issue: 1 year: 2006 ident: 2191_CR29 publication-title: Arthritis Rheum doi: 10.1002/art.21575 – volume: 166 start-page: 4177 issue: 6 year: 2001 ident: 2191_CR10 publication-title: J Immunol doi: 10.4049/jimmunol.166.6.4177 – volume: 70 start-page: 2096 issue: 12 year: 2018 ident: 2191_CR32 publication-title: Arthritis Rheumatol doi: 10.1002/art.40678 – volume: 70 start-page: 259 issue: 2 year: 2011 ident: 2191_CR3 publication-title: Ann Rheum Dis doi: 10.1136/ard.2009.126821 – volume: 27 start-page: 517 issue: 4 year: 2008 ident: 2191_CR43 publication-title: Clin Rheumatol doi: 10.1007/s10067-007-0812-x – volume: 75 start-page: 1099 issue: 6 year: 2016 ident: 2191_CR50 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2014-206785 – volume: 71 start-page: 210 issue: 2 year: 2019 ident: 2191_CR35 publication-title: Arthritis Rheumatol doi: 10.1002/art.40698 – volume: 61 start-page: 1090 issue: 12 year: 2002 ident: 2191_CR22 publication-title: Ann Rheum Dis doi: 10.1136/ard.61.12.1090 – volume: 73 start-page: 861 issue: 5 year: 2014 ident: 2191_CR8 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2012-203130 – volume: 58 start-page: 3009 issue: 10 year: 2008 ident: 2191_CR13 publication-title: Arthritis Rheum doi: 10.1002/art.23936 – volume: 75 start-page: 1876 issue: 10 year: 2016 ident: 2191_CR15 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2015-208495 – volume: 70 start-page: 1946 issue: 12 year: 2018 ident: 2191_CR34 publication-title: Arthritis Rheumatol doi: 10.1002/art.40587 – volume: 14 start-page: R201 issue: 5 year: 2012 ident: 2191_CR18 publication-title: Arthritis Res Ther doi: 10.1186/ar4039 – volume: 88 start-page: 57 issue: 1 year: 2011 ident: 2191_CR2 publication-title: Am J Hum Genet doi: 10.1016/j.ajhg.2010.12.007 – volume: 63 start-page: 26 issue: 1 year: 2011 ident: 2191_CR27 publication-title: Arthritis Rheum doi: 10.1002/art.27758 – volume: 67 start-page: 2032 issue: 8 year: 2015 ident: 2191_CR48 publication-title: Arthritis Rheumatol doi: 10.1002/art.39170 – volume: 64 start-page: 1744 issue: 12 year: 2005 ident: 2191_CR5 publication-title: Ann Rheum Dis doi: 10.1136/ard.2004.033571 – volume: 7 issue: 5 year: 2012 ident: 2191_CR14 publication-title: PLoS One doi: 10.1371/journal.pone.0035296 – volume: 108 start-page: 17372 issue: 42 year: 2011 ident: 2191_CR21 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1114465108 – volume: 6 start-page: R142 issue: 2 year: 2004 ident: 2191_CR11 publication-title: Arthritis Res Ther doi: 10.1186/ar1149 – volume: 68 start-page: 1603 issue: 7 year: 2016 ident: 2191_CR4 publication-title: Arthritis Rheumatol doi: 10.1002/art.39619 – volume: 121 start-page: 3635 issue: 9 year: 2011 ident: 2191_CR47 publication-title: J Clin Invest doi: 10.1172/JCI45790 – volume: 70 start-page: 1732 issue: 11 year: 2018 ident: 2191_CR37 publication-title: Arthritis Rheumatol doi: 10.1002/art.40578 – volume: 31 start-page: 315 issue: 3 year: 1988 ident: 2191_CR23 publication-title: Arthritis Rheum doi: 10.1002/art.1780310302 – volume: 71 start-page: 196 issue: 2 year: 2019 ident: 2191_CR33 publication-title: Arthritis Rheumatol doi: 10.1002/art.40699 – volume: 71 start-page: 1984 issue: 12 year: 2012 ident: 2191_CR44 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2011-201225 – volume: 17 start-page: 97 issue: 1 year: 2015 ident: 2191_CR7 publication-title: Arthritis Res Ther doi: 10.1186/s13075-015-0611-8 – volume: 13 start-page: 641 issue: 8 year: 2012 ident: 2191_CR46 publication-title: Genes Immun doi: 10.1038/gene.2012.46 – volume: 63 start-page: 1079 issue: 9 year: 2004 ident: 2191_CR20 publication-title: Ann Rheum Dis doi: 10.1136/ard.2003.019877 – volume: 35 start-page: 1643 issue: 5 year: 2005 ident: 2191_CR12 publication-title: Eur J Immunol doi: 10.1002/eji.200526000 – volume: 77 start-page: 1044 issue: 6 year: 2005 ident: 2191_CR26 publication-title: Am J Hum Genet doi: 10.1086/498651 |
| SSID | ssj0022924 |
| Score | 2.525443 |
| Snippet | Background
Rheumatoid arthritis (RA) is classified as seropositive or seronegative, depending on the presence/absence of rheumatoid factor (RF), primarily IgM... Rheumatoid arthritis (RA) is classified as seropositive or seronegative, depending on the presence/absence of rheumatoid factor (RF), primarily IgM RF, and/or... Background Rheumatoid arthritis (RA) is classified as seropositive or seronegative, depending on the presence/absence of rheumatoid factor (RF), primarily IgM... Abstract Background Rheumatoid arthritis (RA) is classified as seropositive or seronegative, depending on the presence/absence of rheumatoid factor (RF),... |
| SourceID | doaj swepub pubmedcentral hal proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 170 |
| SubjectTerms | Anti-carbamylated protein antibodies (anti-CarP) Anti-Citrullinated Protein Antibodies Anti-citrullinated protein antibodies (ACPA) Antibodies Antigenic determinants Antigens Arthritis Arthritis, Rheumatoid - diagnosis Autoantibodies Autoimmunity Cyclic citrullinated peptide (CCP) Disease activity score for 28 joints (DAS28) Health screening HLA antigens HLA-DRB1 shared epitope (SE) Human health and pathology Humans Immunoglobulin G Infectious diseases Investigations Life Sciences Medical research Medicine Medicine & Public Health Orthopedics Peptides Peptides, Cyclic Population Research Article Rheumatoid arthritis Rheumatoid arthritis (RA) Rheumatoid Factor Rheumatoid factor (RF) Rheumatology Risk Factors Smoking |
| SummonAdditionalLinks | – databaseName: DOAJ (Directory of Open Access Journals) dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagB8QF8SZQkEE8DhA1m4cfx-VRrRAgDhT1Zjl-dCNQgtoN5574FfDn-kuYcZxAKCoXDitl44nteMbjmXjmMyEPpWCwkHuY34bJtLS1SQUDhjhRWbBeOabtYbTFO7baK1_vV_u_HfWFMWEDPPAwcDvSlWVeMo9AZ6VhAjMnc6trrnWW2QD4mWcyG52p6Grl4FaMKTKC7RyBpuaYiZzBDzyUNJ8tQwGtf9LJ59cYEnna3jwdNjntnf6BMxrWpt3L5FI0KulyeJkr5Jxrr5ILb-O2-TXy7X1IMjKOdp7qftPBcDZ1hwGEtGnpyfF3EMSudQcBBfzk-Ac9XLsebNmusRSGaB2Qj6iOrISn8PMtNWh5I5MpBqjTeHQP1a2liIJM4-YPxdwJPKLiOtnbffXhxSqNBzCkBtyoTcpElWmLSiBntvI-5w7MH1OUXtbCGAerW6GdLqTz1mZS-JKZGv4WQnvhwVC4QbZa6P0tQp302cIwcE8sWmhc1I5bDoRFiLKtErIY-aFMRCfHQzI-q-ClCKYGHirgoQo8VHlCnk7PfBmwOc6kfo5snigRVzvcAGlTUdrUv6QtIU9QSBTOfuie0TGJAV4ScbTUkoGOlFXOobntGSXMWjMrfgBiNuvMavlG4T08dwO_y31dQB2jFKqoWo4U5vNwsDe4SMj9qRirx3C51nX9QAOOrJBQxc1BaKemwF7n4CVACZ-J86wv85K2WQfgcY571gW0-2wU_F_dOmvgHw2TY9bCy-bjMgx936sSE7R5Qh7_hS7e-gRXTpVMMp7d_h-cvEMu5kEf8HTBtsnW5rB3d8G-3NT3gir5CQD0dqw priority: 102 providerName: Directory of Open Access Journals – databaseName: PHMC-Proquest健康医学期刊库 dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR3JbhMx1KJFQlwQe0MLMojlAKPO6uWEwlJFCBAHinKzPLaniUAzbZLh3BNfAT_XL-E9jzPRUJRDpGT8xnb8Fr9nv4WQp1Iw2Mgr4G_DZJTb0kSCAUKcKCxorxzD9tDb4jObHOcfpsU0HLgtg1vlWiZ6QW0bg2fkhxjGwEHMcvH69CzCqlF4uxpKaOyQqwloIli6gU83Blcqu6K2OVhKsLHm66AZwQ6XILs5xibH8AGbJUoHG5PP399L6Z0ZOkle1kAvO1L2t6n_ZB71u9XRTXIjqJl03NHFLXLF1bfJtU_hIv0O-fXFhx0ZR5uK6nbVwALPywZdCum8phfnv4E0m9qd-LzgF-d_6GLmWtBum7mlQG0znwuJ6oBceAsPdKlBXRzRTtFlnYZiPlTXlmJeZBqugyhGU2DRirvk-Oj917eTKJRkiAwYVquIiSLWFsVCymxRVSl3oBCZLK9kKYxxsN9l2ulMusraWIoqZ6aEn5nQlahAdbhHdmuY_R6hTlZxYhgYLBZ1Ni5Kxy0HwMz73RYjkqzxoUzIV45lM34ob7cIpjocKsCh8jhU6Yi87N857bJ1bIV-g2juITHTtn_QLE5UYFwlXQ6UxypMtJcbJjByN7W65FrHsU3kiLxAIlEoD2B6RoewBviTmFlLjRlITVmkHIY7GEACH5tB8xMgs8FkJuOPCp9hJQ48qfuZQB9rKlRB2CzVhjVG5HHfjN2jA13tmraDAdNWSOjifke0_VCgwXOwG6CFD8h5MJdhSz2f-VTkHG-xMxj31ZrwN9PatvDPOuYYjPBu_m3sl75tVY4h23xEnv8HLjz6Dt-cyplkPH6wfVn2yfXUczqPEnZAdleL1j0EXXJVPvIC4y_n-HDq priority: 102 providerName: ProQuest |
| Title | Presence of autoantibodies in “seronegative” rheumatoid arthritis associates with classical risk factors and high disease activity |
| URI | https://link.springer.com/article/10.1186/s13075-020-02191-2 https://www.ncbi.nlm.nih.gov/pubmed/32678001 https://www.proquest.com/docview/2424712378 https://www.proquest.com/docview/2424996891 https://ut3-toulouseinp.hal.science/hal-03152228 https://pubmed.ncbi.nlm.nih.gov/PMC7364538 https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-420437 http://kipublications.ki.se/Default.aspx?queryparsed=id:144266058 https://doaj.org/article/9e44246f67784c6896472dab7aa00d19 |
| Volume | 22 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlR3LbhMx0KKthLgg3gRKZBCPA6zYpx_HNLSKEFQVIig3y2t7SQTaRW2Wc098Bfxcv4QZr7OwtKrEIVHWHj-y8_CMPTMm5KkUDBbyCvjbMBnltjSRYIAQJwoL2ivHsD30tjhks3n-dlEsQpocjIX5-_w-Eez1CchYjjHEMXzAtohA3O4UUIjUPGXT3rhKwZDYBMVc2G6w8Pj8_L0U3lqiE-R5DfO8o2R_WvpPZlG_Gh3cINeDGkknHd5vkiuuvkWuvg8H5bfJjyMfVmQcbSqq23UDL3BVNugySFc1PTv9CaTX1O6zz_t9dvqLHi9dC9prs7IUqGnpcx1RHZAHrXDDlhrUtRGtFF3Sabish-raUsx7TMNxD8VoCbyU4g6ZH-x_nM6icOVCZMBwWkdMFLG2yPYps0VVpdyBwmOyvJKlMMbBepZppzPpKmtjKaqcmRIeM6ErUYFqcJds1zD7-4Q6WcWJYWCQWNTJuCgdtxwAM-9XW4xIssGHMiEfOV6L8VV5u0Qw1eFQAQ6Vx6FKR-Rl3-Zbl43jUug9RHMPiZm0fQEQmAqMqaTL8zRnFSbSyw0TGJmbWl1yrePYJnJEXiCRKOR3mJ7RIWwB_iRmzlITBlJRFimH4XYHkMCnZlD9BMhsMJnZ5J3CMrxpA3fivifQx4YKVRAmJwojeDhoGFyMyOO-GrtHB7naNW0HA6arkNDFvY5o-6FAQ-dgF0ANH5DzYC7Dmnq19KnGOZ5SZzDuqw3h_5nWZS_-WcccgxHerD5N_KtvW5VjSDYfkecXwIWiL_DLqZxJxuMH_zf-Q3ItBV0UvY4SsUu218etewS647ocky2-4GOys7d_ePRh7EXI2O_DwPc8nfwGSmZsMQ |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3LbtQw0Gq3EnBBvFkoYBCFA0TNJlnbOVRoS1tt6baqUFv1ZhLb6a5ASdkHiFtPfAX8Ch_TL2HGcVKFor31sNKuPbG9mfE87HkQ8jIWDAR5BvtbsdiLdKo8wQAhRnQ1aK8cw_bQ22KP9Q-jD8fd4wXyp4qFQbfKiidaRq0LhWfkqxjGwIHNcvHu9KuHVaPwdrUqoZG40gp6zaYYc4EdO-bHdzDhJmvbG4DvlSDY2jx43_dclQFPga0w9Zjo-olGSg-Y7mZZwA3IeBVGWZwKpQyw8DAxSRibTGs_FlnEVAo_Q5FkIgNpCOMukqUID1BaZGl9c2__Y23yBXFZVjcCWw1Ee1SF7Qi2OgHpwTE62ocPWE1e0BCNtoJALScWh-imeVkHvuzKWd_n_pP71MrLrVvkplN0aa-kzNtkweR3yLVdd5V_l_zct4FPytAio8lsWgCKR2mBTo10lNPzs1-wOYrcnNjM5Odnv-l4aGagXxcjTYHehzYbE00cecFTeKRMFVoDSHgUneapKydEk1xTzMxM3YUUxXgOLJtxjxxeCbruk1YOq39IqIkzv6MYmEwatUYuUsM1B8DQev5226RT4UMqlzEdC3d8kdZyEkyWOJSAQ2lxKIM2eVM_c1rmC5kLvY5oriEx17dtKMYn0rEOGZsIaJ9lmOovUkxg7HCgk5Qnie_rTtwmr5FIJHIkWJ5KXGAF_EnM7SV7DPh23A04TLfcgAROohrdL4DMGovp9wYS27AWCJ4VfuvAGBUVSsfuJvJic7bJ87obh0cXvtwUsxIGjGsRwxAPSqKtpwIbgoPlAj28Qc6NtTR78tHQJkPneI8ewrxvK8K_WNa8F79Sbo7GDBujo5599bOZjDBonLfJq__AuabP8M3IiMWM-4_mv5Zn5Hr_YHcgB9t7O4_JjcDueu512DJpTccz8wQ022n61LEPSj5dNcf6C2iytQo |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELagSBUXxJtAAYN4HCBqNnFs57hQVguUqgcW9WY5fnRXoKTabjj3xK-AP9dfwoyTDYRWlTistGtPbK9nPJ6JZz4T8qyQHDZyD-vb8CJmtjSx5MAQJ3ML1qvAtD2Mttjj0xn7cJAf_JXFH6Ld10eSbU4DojRVq-0j69slLvn2MWhegZnFCXzA44hBCV9hsFdjUNcsHfcuVwruxTpV5tznBttRQO3vdfPlOYZGnrU7z4ZP9meo_-CNhj1qcp1c64xLOm6l4Qa55KqbZPNTd3x-i_zYD8lGxtHaU92sapjWRVljICFdVPT05CcIZF25w4AGfnryiy7nrgGbtl5YCjI2DwhIVHcshafwNS41aIEjsykGqtPuCh-qK0sRDZl2h0AUcyjwqorbZDZ59_ntNO4uYogNuFOrmMs80RaVQcpt7n0qHJhBJmO-KKUxDna5TDudFc5bmxTSM25K-JlJ7aUHg-EO2ahg9PcIdYVPRoaDm2LRUhOydMIKIMxCtG0ekdGaH8p0KOV4WcY3FbwVyVXLQwU8VIGHKo3Iq_6Zoxaj40LqN8jmnhLxtUNBvTxU3XJVhWMsZdwjvB4zXGK-bmp1KbROEjsqIvIShUShFoDhGd0lM8CfRDwtNeagK4s8FdDd1oASVq8ZVD8FMRsMZjreVViG92_g-7nvI2hjLYWqUzHHCvN6BNgdQkbkSV-NzWPYXOXqpqUBh1YW0MTdVmj7rsBuF-AtQI0YiPNgLMOaajEPAOQCz64z6Pf1WvD_DOuiiX_eLo5BDzuLL-Mw9U2jGCZqi4i8OIeuK_oK35xivOAiuf9__T8mm_s7E7X7fu_jA3I1DUpAxCO-RTZWy8Y9BONyVT4K-uM3ecNzJg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Presence+of+autoantibodies+in+%22seronegative%22+rheumatoid+arthritis+associates+with+classical+risk+factors+and+high+disease+activity&rft.jtitle=Arthritis+research+%26+therapy&rft.au=Reed%2C+Evan&rft.au=Hedstr%C3%B6m%2C+Anna+Karin&rft.au=Hansson%2C+Monika&rft.au=Mathsson-Alm%2C+Linda&rft.date=2020-07-16&rft.pub=BioMed+Central+Ltd&rft.issn=1478-6354&rft.volume=22&rft.issue=1&rft_id=info:doi/10.1186%2Fs13075-020-02191-2&rft.externalDocID=A631895272 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1478-6362&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1478-6362&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1478-6362&client=summon |